TrialPath
Recruiting

International Validation of Two Non-motor Scales in PD (NFS and SPARK)

NCT04366804 · Insel Gruppe AG, University Hospital Bern
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
International Validation of Two Non-motor Scales in Parkinson's Disease: the Neuropsychiatric Fluctuations Scale (NFS) and the Shame in Parkinson's Disease (SPARK) Scale
About this study
This project is a prospective international multicentre study to validate two new rating scales in different languages: the Neuropsychiatric Fluctuations Scale (NFS) and the Shame in PARKinson's disease (SPARK) Scale. The project population consists a minimum of 300 PD patients with and without fluctuations in the participant countries: Spain, Germany, France, Switzerland, Romania and Greece. The NFS is specifically designed to detect neuropsychiatric fluctuations between off- and on-medication condition in PD. It is composed of 20 items, 10 items measuring the on-neuropsychological symptoms and 10 items for the off-neuropsychological manifestations. The validation of this scale, based on the most frequently experienced symptoms by the patients, would allow a crucial breakthrough in the improvement of management of PD patients. Shame and embarrassment are poorly recognized by physicians in PD. PD-related shame and embarrassment may emerge from motor and non-motor symptoms, from self-perception of inadequacy due to loss of autonomy and need for help, or from perceived deterioration of body image. The current available scales are not specific for PD. Based on reports of persons affected with PD and a literature review about shame and stigmatization in PD a 25-items self-questionnaire for shame and embarrassment in PD was created. The scale includes 6 different subscales (1. Shame arising from PD symptoms; 2. Shame arising from the increasing physical dependence and need for help induced by PD; 3. Shame arising from the patient's assumption of breaking certain social rules; 4. Shame arising from the deteriorated body image; 5. Consequence of related shame and embarrassment on patients' health-related quality of life; 6. Stigmatization). The validation of this scale will give a tool for physicians and researchers to better understand the impact of PD on patient's quality of life.
Eligibility criteria
Inclusion Criteria: 1. Written informed consent; 2. PD, according to the MDS criteria; 3. Age of participants \> 30 and \< 75 years; 4. Being fluent in the language in which the scales are applied. Exclusion Criteria: 1\. Presence of PD dementia (defined as MoCA score \< 24).
Study design
Enrollment target: 300 participants
Age groups: adult, older_adult
Timeline
Starts: 2020-12-03
Estimated completion: 2025-12-31
Last updated: 2025-04-13
Primary outcomes
  • NFS score (2 weeks (2 assessments in a time span of 2 weeks))
  • SPARK score (2 weeks (2 assessments in a time span of 2 weeks))
Sponsor
Insel Gruppe AG, University Hospital Bern · other
With: Michael J. Fox Foundation for Parkinson's Research, Carlos III Health Institute
Contacts & investigators
ContactInes Debove, MD · contact · ines.debove@insel.ch · +41 31 63 2 79 24
InvestigatorPaul Krack, MD, PhD · principal_investigator, Insel Gruppe AG, University Hospital Bern
All locations (8)
Centre hospitalier régional universitaire de BesançonCompleted
Besançon, France
Universitätsklinikum Carl Gustav CarusCompleted
Dresden, Germany
Aristotle University of ThessalonikiCompleted
Thessaloniki, Greece
Transilvania UniversityRecruiting
Brasov, Romania
Hospital Universitario BurgosCompleted
Burgos, Spain
Ruber International HospitalCompleted
Madrid, Spain
Insel Gruppe AG University Hospital BernCompleted
Bern, Switzerland
King's College LondonRecruiting
London, United Kingdom